[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.198.71. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo Updates
April 11, 2001

Treatment of Primary Cutaneous Melanoma

Author Affiliations

Author Affiliations: Division of Dermatology, Santa Clara Valley Medical Center, San Jose, Calif (Dr Kanzler) and Department of Dermatology, Stanford University School of Medicine (Drs Kanzler and Mraz-Gernhard), Stanford, Calif.

 

Contempo Updates Section Editor: Alice T. D. Hughes, MD, Fishbein Fellow.

JAMA. 2001;285(14):1819-1821. doi:10.1001/jama.285.14.1819

With a lack of scientific data, standard of care for treatment of patients with melanoma at the beginning of the 20th century called for extensive mutilating surgery and/or local amputation of involved body areas. In the mid-1900s, aggressive lymph node dissections were popular in an attempt to control metastatic disease despite the lack of scientific data that such procedures did, indeed, affect the survival of patients with melanoma. The treatment of melanoma has changed significantly in the intervening years, and can now be guided by data regarding clinical outcomes. The purpose of this review is to present clinicians with an evidence-based summary of the current literature regarding therapy for primary cutaneous melanoma.

First Page Preview View Large
First page PDF preview
First page PDF preview
×